Target Price | $322.83 |
Price | $259.30 |
Potential | 24.50% |
Number of Estimates | 23 |
23 Analysts have issued a price target Amgen 2025 . The average Amgen target price is $322.83. This is 24.50% higher than the current stock price. The highest price target is $405.00 56.19% , the lowest is $195.00 24.80% . | |
A rating was issued by 34 analysts: 15 Analysts recommend Amgen to buy, 16 to hold and 3 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Amgen stock has an average upside potential 2025 of 24.50% . Most analysts recommend the Amgen stock at Hold. |
27 Analysts have issued a sales forecast Amgen 2024 . The average Amgen sales estimate is $33.2b . This is 2.65% higher than the revenue of the last 12 months(TTM). The highest sales forecast is $33.5b 3.75% , the lowest is $32.9b 1.78% .
This results in the following potential growth metrics:
2023 | $28.0b | 7.35% |
---|---|---|
2024 | $33.2b | 18.46% |
2025 | $34.4b | 3.73% |
2026 | $34.9b | 1.43% |
2027 | $35.5b | 1.72% |
2028 | $36.3b | 2.20% |
5 Analysts have issued an Amgen EBITDA forecast 2024. The average Amgen EBITDA estimate is $14.3b . This is 18.06% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is $15.8b 30.74% , the lowest is $10.1b 16.45% .
This results in the following potential growth metrics and future EBITDA Margins:
2023 | $12.4b | 1.91% |
---|---|---|
2024 | $14.3b | 15.47% |
2025 | $17.8b | 24.47% |
2026 | $17.9b | 0.85% |
2027 | $19.3b | 7.76% |
2028 | $19.7b | 2.06% |
2023 | 44.11% | 8.62% |
---|---|---|
2024 | 43.00% | 2.52% |
2025 | 51.60% | 20.00% |
2026 | 51.31% | 0.56% |
2027 | 54.36% | 5.94% |
2028 | 54.28% | 0.15% |
11 Amgen Analysts have issued a net profit forecast 2024. The average Amgen net profit estimate is $4.8b . This is 15.26% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is $6.3b 49.30% , the lowest is $4.1b 3.19% .
This results in the following potential growth metrics and future Net Margins:
2023 | $6.7b | 3.14% |
---|---|---|
2024 | $4.8b | 27.92% |
2025 | $5.9b | 22.55% |
2026 | $6.5b | 10.31% |
2027 | $9.1b | 38.89% |
2028 | $10.0b | 9.74% |
2023 | 23.97% | 3.92% |
---|---|---|
2024 | 14.58% | 39.17% |
2025 | 17.23% | 18.18% |
2026 | 18.74% | 8.76% |
2027 | 25.59% | 36.55% |
2028 | 27.48% | 7.39% |
11 Analysts have issued a Amgen forecast for earnings per share. The average Amgen <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is $9.00 . This is 15.24% higher than earnings per share in the financial year 2023. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is $11.66 49.30% , the lowest is $7.56 3.20% .
This results in the following potential growth metrics and future valuations:
2023 | $12.49 | 3.14% |
---|---|---|
2024 | $9.00 | 27.94% |
2025 | $11.03 | 22.56% |
2026 | $12.17 | 10.34% |
2027 | $16.90 | 38.87% |
2028 | $18.55 | 9.76% |
Current | 33.63 | 66.40% |
---|---|---|
2024 | 29.18 | 13.23% |
2025 | 23.81 | 18.40% |
2026 | 21.58 | 9.37% |
2027 | 15.54 | 27.99% |
2028 | 14.16 | 8.88% |
Based on analysts' sales estimates for 2024, the Amgen stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of 5.80 and an <a href=https://blog.stocksguide.com/knowledge/price-sales-ratio-simply-explained>P/S ratio of 4.26 .
This results in the following potential growth metrics and future valuations:
Current | 5.96 | 10.78% |
---|---|---|
2024 | 5.80 | 2.62% |
2025 | 5.60 | 3.60% |
2026 | 5.52 | 1.41% |
2027 | 5.42 | 1.69% |
2028 | 5.31 | 2.15% |
Current | 4.37 | 23.52% |
---|---|---|
2024 | 4.26 | 2.58% |
2025 | 4.10 | 3.60% |
2026 | 4.04 | 1.41% |
2027 | 3.98 | 1.69% |
2028 | 3.89 | 2.15% |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.